Literature DB >> 27039252

Makings of a brittle bone: Unexpected lessons from a low protein diet study of a mouse OI model.

E L Mertz1, E Makareeva1, L S Mirigian1, K Y Koon1, J E Perosky2, K M Kozloff2, S Leikin3.   

Abstract

Glycine substitutions in type I collagen appear to cause osteogenesis imperfecta (OI) by disrupting folding of the triple helix, the structure of which requires Gly in every third position. It is less clear, however, whether the resulting bone malformations and fragility are caused by effects of intracellular accumulation of misfolded collagen on differentiation and function of osteoblasts, effects of secreted misfolded collagen on the function of bone matrix, or both. Here we describe a study originally conceived for testing how reducing intracellular accumulation of misfolded collagen would affect mice with a Gly610 to Cys substitution in the triple helical region of the α2(I) chain. To stimulate degradation of misfolded collagen by autophagy, we utilized a low protein diet. The diet had beneficial effects on osteoblast differentiation and bone matrix mineralization, but also affected bone modeling and suppressed overall animal growth. Our more important observations, however, were not related to the diet. They revealed how altered osteoblast function and deficient bone formation by each cell caused by the G610C mutation combined with increased osteoblastogenesis might make the bone more brittle, all of which are common OI features. In G610C mice, increased bone formation surface compensated for reduced mineral apposition rate, resulting in normal cortical area and thickness at the cost of altering cortical modeling process, retaining woven bone, and reducing the ability of bone to absorb energy through plastic deformation. Reduced collagen and increased mineral density in extracellular matrix of lamellar bone compounded the problem, further reducing bone toughness. The latter observations might have particularly important implications for understanding OI pathophysiology and designing more effective therapeutic interventions. Published by Elsevier B.V.

Entities:  

Keywords:  Biomechanics; Bone; Collagen; Mineralization; Osteogenesis imperfecta; Raman microspectroscopy

Mesh:

Substances:

Year:  2016        PMID: 27039252      PMCID: PMC5061452          DOI: 10.1016/j.matbio.2016.03.005

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  34 in total

1.  The mineralization density of iliac crest bone from children with osteogenesis imperfecta.

Authors:  A Boyde; R Travers; F H Glorieux; S J Jones
Journal:  Calcif Tissue Int       Date:  1999-03       Impact factor: 4.333

2.  The elastic and ultimate properties of compact bone tissue.

Authors:  D T Reilly; A H Burstein
Journal:  J Biomech       Date:  1975       Impact factor: 2.712

3.  Contribution of collagen and mineral to the elastic-plastic properties of bone.

Authors:  A H Burstein; J M Zika; K G Heiple; L Klein
Journal:  J Bone Joint Surg Am       Date:  1975-10       Impact factor: 5.284

4.  Isolation of the stromal-vascular fraction of mouse bone marrow markedly enhances the yield of clonogenic stromal progenitors.

Authors:  Colby Suire; Nathalie Brouard; Karen Hirschi; Paul J Simmons
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

5.  TGF-beta regulates the mechanical properties and composition of bone matrix.

Authors:  Guive Balooch; Mehdi Balooch; Ravi K Nalla; Stephen Schilling; Ellen H Filvaroff; Grayson W Marshall; Sally J Marshall; Robert O Ritchie; Rik Derynck; Tamara Alliston
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-14       Impact factor: 11.205

6.  Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection.

Authors:  Yoshihito Ishida; Akitsugu Yamamoto; Akira Kitamura; Shireen R Lamandé; Tamotsu Yoshimori; John F Bateman; Hiroshi Kubota; Kazuhiro Nagata
Journal:  Mol Biol Cell       Date:  2009-04-08       Impact factor: 4.138

7.  Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.

Authors:  Christina M Jacobsen; Lauren A Barber; Ugur M Ayturk; Heather J Roberts; Lauren E Deal; Marissa A Schwartz; MaryAnn Weis; David Eyre; David Zurakowski; Alexander G Robling; Matthew L Warman
Journal:  J Bone Miner Res       Date:  2014-10       Impact factor: 6.741

8.  Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.

Authors:  Kenneth M Kozloff; Angela Carden; Clemens Bergwitz; Antonella Forlino; Thomas E Uveges; Michael D Morris; Joan C Marini; Steven A Goldstein
Journal:  J Bone Miner Res       Date:  2004-01-12       Impact factor: 6.741

9.  Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta.

Authors:  Antonella Forlino; Chiara Tani; Antonio Rossi; Anna Lupi; Elena Campari; Benedetta Gualeni; Laura Bianchi; Alessandro Armini; Giuseppe Cetta; Luca Bini; Joan C Marini
Journal:  Proteomics       Date:  2007-06       Impact factor: 3.984

10.  Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration.

Authors:  Paolo Grumati; Luisa Coletto; Patrizia Sabatelli; Matilde Cescon; Alessia Angelin; Enrico Bertaggia; Bert Blaauw; Anna Urciuolo; Tania Tiepolo; Luciano Merlini; Nadir M Maraldi; Paolo Bernardi; Marco Sandri; Paolo Bonaldo
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

View more
  7 in total

Review 1.  Extracellular matrix: The driving force of mammalian diseases.

Authors:  Renato V Iozzo; Maria A Gubbiotti
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

2.  mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy.

Authors:  Rosa Bartolomeo; Laura Cinque; Chiara De Leonibus; Alison Forrester; Anna Chiara Salzano; Jlenia Monfregola; Emanuela De Gennaro; Edoardo Nusco; Isabella Azario; Carmela Lanzara; Marta Serafini; Beth Levine; Andrea Ballabio; Carmine Settembre
Journal:  J Clin Invest       Date:  2017-09-05       Impact factor: 14.808

3.  The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta.

Authors:  Roberta Gioia; Francesca Tonelli; Ilaria Ceppi; Marco Biggiogera; Sergey Leikin; Shannon Fisher; Elena Tenedini; Timur A Yorgan; Thorsten Schinke; Kun Tian; Jean-Marc Schwartz; Fabiana Forte; Raimund Wagener; Simona Villani; Antonio Rossi; Antonella Forlino
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

4.  Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.

Authors:  John F Bateman; Lisa Sampurno; Antonio Maurizi; Shireen R Lamandé; Natalie A Sims; Tegan L Cheng; Aaron Schindeler; David G Little
Journal:  J Cell Mol Med       Date:  2018-12-30       Impact factor: 5.310

5.  ER, Mitochondria, and ISR Regulation by mt-HSP70 and ATF5 upon Procollagen Misfolding in Osteoblasts.

Authors:  Laura Gorrell; Elena Makareeva; Shakib Omari; Satoru Otsuru; Sergey Leikin
Journal:  Adv Sci (Weinh)       Date:  2022-08-21       Impact factor: 17.521

6.  A novel variant of osteogenesis imperfecta type IV and low serum phosphorus level caused by a Val94Asp mutation in COL1A1.

Authors:  Qi Yang; Hong Xu; Jinsi Luo; Qinle Zhang; Bobo Xie; Sheng Yi; Xiuliang Rong; Jin Wang; Zailong Qin; Tingting Jiang; Li Lin; Yangjin Zuo; Xin Fan
Journal:  Mol Med Rep       Date:  2018-01-16       Impact factor: 2.952

7.  Substitutions for arginine at position 780 in triple helical domain of the α1(I) chain alter folding of the type I procollagen molecule and cause osteogenesis imperfecta.

Authors:  Elena Makareeva; Guoli Sun; Lynn S Mirigian; Edward L Mertz; Juan C Vera; Nydea A Espinoza; Kathleen Yang; Diana Chen; Teri E Klein; Peter H Byers; Sergey Leikin
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.